Research

  SP Pain met during recent EAN Congress in Amsterdam. Co-chair Nadine Attal from France welcomed members and presented last year panel’s activities. Last year was successful. SP Pain co-chairs Nadine Attal and Giorgio Cruccu had, together with members of… Continue Reading

  SP Neurotraumatology met during recent EAN Congress in Amsterdam. Co-chairs Pieter Vos from the Netherlands and Oliver Kastrup from Germany welcomed members and introduced Dafin Muresanu from Romania, as a new liaison officer between the scientific committee and scientific… Continue Reading

For September 2017, we have selected: Hoffman EM, Watson JC, St Sauver J, Staff NP, Klein CJ. Association of long-term opioid therapy with functional status, adverse outcomes, and mortality among patients with polyneuropathy. JAMA Neurology 2017;74:773-779. Neuropathic pain is a common symptom in polyneuropathy that can be difficult to manage. Opioids are usually recommended as second-line treatment, with primary care physicians being mainly involved in opioid prescription.

Antonio Federico: What are the aims of your ERN? Helen Cross: The objectives of the EpiCARE network will be: To improve accessibility of detailed diagnostics to individuals of all ages with rare and complex epilepsies across Europe, including clinical evaluation and investigation.

A session on neurological palliative care was included within the 15th World Congress of the European Association for Palliative Care in Madrid on 18th May.  In 2016, a Memorandum of Understanding was signed between the EAPC and the EAN and… Continue Reading

ntonio Federico: What are the aims of your ERN? Teresinha Evangelista: Our MISSION: Through collaborative cross-border work the EURO-NMD ERN will improve the lives of EU citizens by improving diagnosis, treatment and the delivery of high-quality, accessible and cost-effective healthcare to patients with rare Neuromuscular Diseases (NMD) requiring a particular concentration of resources or expertise.

The EAN Rare neurological diseases task force will be holding its 1st teaching course under the auspices of Dafin F. Muresanu, Professor of Neurology at the “Iuliu Hatieganu” University of Medicine and Pharmacy, in Cluj-Napoca, Romania. This teaching course aims… Continue Reading

or August 2017, we have selected: The Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled trial. Lancet Neurol 2017;16:505-512. There is evidence that oxidative stress induced by free radicals is a key factor of progression in amyotrophic lateral sclerosis (ALS).

Please find below articles from Serbian authors and co-authors that were published in the European Journal of Neurology.

For July 2017, we have selected: Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia. Neurology 2017;88:2003-2010. Tardive dyskinesia (TD) is a relatively frequent complication of antipsychotic treatment. TD can be observed in any part of the body, can be very disabling, and often persists even after stopping the causative medication.

The Brain Prize is now open to researchers around the world   The Brain Prize was launched in 2011 and was awarded for the 7th time this year to Peter Dayan, Wolfram Schultz and Ray Dolan for their work on… Continue Reading

This year, The Brain Prize – the world’s most valuable prize for brain research – was awarded to Peter Dayan, Ray Dolan and Wolfram Schultz for their analysis of how the brain recognises and processes reward. The prize was presented… Continue Reading

For June 2017, we have selected: Breitenstein C, Flöel A, Ziegler W, et al., for the FCET2EC study group. Intensive speech and language therapy in patients with chronic aphasia after stroke: a randomized, open-label, blinded-endpoint, controlled trial in health-care setting. Lancet Neurol 2017;389:1528-1538. Speech and language impairments are among the most disabling symptoms after a stroke. Patients with aphasia persisting 6 months (chronic aphasia) after a stroke are not infrequent (20%). Hence, the social and economic impact of chronic aphasia is substantial.